• Citius Pharmaceuticals Inc CTXR.OQ reported a quarterly adjusted loss of $1.27​​ per share for the quarter ended March 31, lower than the same quarter last year, when the company reported EPS of $-1.25. The mean expectation of three analysts for the quarter was for a loss of 4 cents per share. Wall Street expected results to range from $-1.37 to $1.30 per share.

• Reported revenue was zero​; analysts expected $2.67 million.

• Citius Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.27​.

• The company reported a quarterly loss of $10.92 million.

• Citius Pharmaceuticals Inc shares had fallen by 47.2% this quarter and lost 80.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 88.3% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• Wall Street's median 12-month price target for Citius Pharmaceuticals Inc is $4.00

This summary was machine generated from LSEG data May 14 at 09:12 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)